Analyst Ratings For NASDAQ:TRIL – Trillium Therapeutics (NASDAQ:TRIL)
Today, Leerink Swann initiated coverage on NASDAQ:TRIL – Trillium Therapeutics (NASDAQ:TRIL) with a Market Perform with a price target of $7.00.
Some recent analyst ratings include
- 4/13/2018-Leerink Swann initiated coverage with a Market Perform rating.
- 7/5/2017-Cowen Reiterated Rating of Buy.
- 6/9/2017-Ladenburg Thalmann Reiterated Rating of Buy.
- 11/4/2016-Bloom Burton Reiterated Rating of Buy.
- 10/6/2016-BTIG Research initiated coverage with a Buy rating.
- 6/6/2016-Oppenheimer Reiterated Rating of Buy.
Recent Trading Activity for NASDAQ:TRIL – Trillium Therapeutics (NASDAQ:TRIL)
Shares of NASDAQ:TRIL – Trillium Therapeutics closed the previous trading session at 7.05 +0.00 0.00% with 7.050000190734863 shares trading hands.